We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Polarean Imaging Plc | POLX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.05 | -1.32% | 3.75 | 14:28:34 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.80 | 3.75 | 3.80 | 3.75 | 3.80 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 10/4/2024 10:03 by goldbutler Polarean technology may be first class but UK investors responsiblefor financing it to this stage have had no return from it. The CEO only refers to two shareholder groups. Why have they left fund raise until now - are they running down the clock to the last two minutes- is it a shakedown. |
Posted at 05/4/2024 13:53 by goldbutler Commercialisation is not happening quick enough in light of the current finances - the company was expecting Duke university at around the end of Q1- so anytime now.There is no solid reason why they cannot have Philips for one example, market in UK ,Europe or UAE or other arabian gulf and middle eastern states where there is a big COPD problem. Mr Archer has a good review of the small cap brokers and market makers Is the small cap market broken by charles archer Investing Strategy The goose lays the golden egg. Be careful not to slaughter it If the FCA will not regulate, and the market makers will not make a market, and the brokers will not offer finance on reasonable terms — then investors will not invest. |
Posted at 05/4/2024 11:13 by goldbutler During his interview on Proactive investors 3 months agoDr Von Jacko said Polarean was talking to a number of really good potential partners. He went on to say he was talking to a number of Foundations. There is no doubt that Cystic Fibrosis Foundation will be one of those and it had been mentioned by Mr Hullihen previous CEO and mentioned on presentation. That Cystic Fibrosis Foundation received $3.3 Billion when it sold royalty rights for the drug Kalydeco - the plan to expand current FDA approval to age group from 12 onwards will have this Foundation as a potential partner for their 35000 patients. |
Posted at 04/4/2024 12:31 by goldbutler The Board of Directors including Bracco representative director and Nukemsaid that 9 conversions were planned for 2 years wave 1 and wave 2 Wholly inadequate for the company survival funded by 27 million pounds and more from AIM investors On a monthly basis 28 people receive a very handsome pay cheque and the CEO cannot bring himself to refer to shareholders He never stops on Linkedin including references to a previous company So where is the investor presentaion for AIM INVESTORS for wave 1 and 2 Wave 1 Wave 2 Ohio Texas Missouri Iowa N.Carolina Kansas Virginia Illinois Wisconsin Where is the commercial strategy including partnerships for sales into UK and Europe and arab states where there is no shortage of cash and significant COPD problem. Why would any board of directors behave like this and for 18 months warn and advise of a cash raise and see the share price destruction. |
Posted at 14/3/2024 09:47 by dym turbo Cherster, did you read the RNS from Amati this morning?When you see Strategic Review in the title of an RNS on AIM you know there is a mess at play! I can 100% guarantee you that Amait would not be selling their stake to Nukem at 5p when the 2 main Strategic Investors have confirmed they will back to company long term! We all know Amati wanted the POLX sold last year and they also blocked the 40p fundraise in April! Mmmm, I wonder why?? I’m sorry to see Amati go and feel they have been an excellent investor to POLX over the years but that RNS this morning was peppering over the cracks of a horrendous few years for the them – end of story! |
Posted at 14/3/2024 08:50 by wetdream Imho Amati deserve a lot of credit for supporting POLX over the years.Like many investors in the company, they were misled by the overconfidence and inactivity of the BoD during the crucial post- CRL period. Add to that the fact that AIM’s become a graveyard for small biotech and medtech companies and you have a perfect storm. Top it all off with an exclusive US-centric strategy with an inadequate infrastructure to implement it and you can see why they are where they are. |
Posted at 03/3/2024 21:51 by goldbutler No Investor presentation - no questions and no answers.a free run for the Directors. If 150 million shares are issued and nukem take 50 and Bracco 40 they will end up with just about 35% of the company. Is that by chance or very clever? is it any wonder that asset managers question the destruction of the share price since the last fund raise back as far as the IPO. UK Institutional investors need to be more active. The Chairman and board refuse to market in the UK to NHS or Private Health Care. They have no difficulty in applying for a UK grant of several million to fund their activity in the USA. The sales forecast in the USA for the next two years is dreadful. A reminder that this Chairman and Board of Directors including Nukem are not fit for purpose and are directly responsible for the poor sales forecasts , commercial strategy, commercial traction and the current state of the company and share price. |
Posted at 29/2/2024 07:40 by john henry Strategic investors committed funding, funding from UK government.Additional few millions quid required from Investors. Im guessing the board will invest along with a few new Institutions. What price ? imho 5-10p |
Posted at 15/12/2023 00:12 by w t tutte @ GoldButter - Why is it worth repeating ? Mr Gerber is a nobody clearly sitting on big losses. Nobody would care about being thanked if we were at 150p share price.As to disconnect between the technology and the share price I think that is pretty easy to explain. 1) It listed as not much more than an idea and with huge regulatory and capital needs. 2) Richard Huillihan basically worked a miracle in terms of getting all of the elements together and getting it FDA approved. 3) It got swept up in the post pandemic 0% interest retail craze (think Justin Waite and his 100x claims) 4) All those who should never have been in the stock and that includes Amati have now puked it out 5)Buying has yet to return both to the UK small cap space and med tech in particular. Was listed far too early by "characters" and was only listed in the UK because US investors understood well the regulatory process/risks and hurdles that needed to be overcome. The irony is that it is now massively derisked and is from a US perspective "investable" but once again UK investors are unable to see it or at very least to grasp the opportunity .... That just means more for you and me. Probably gets taken out at a ludicrously low price (still multiples of where we sit today)and will prove once again that UK capital markets do not know how to value anything other than Banks, insurance companies, utilities and possibly resources/oil companies. |
Posted at 24/10/2023 16:07 by john henry Strategic investors who know this business far better than PEEPS posting here will imho provide funding.Worth remembering this recent appointment, Christopher von Jako, Ph.D., CEO of Polarean, said: "We are delighted to welcome Bill to the Board of Polarean. We felt it was important to have someone with further experience of the UK healthcare sector and with AIM-listed companies on the Board. Following conversations with Amati Global Investors, our largest shareholder, and several other shareholders, we identified Bill as the ideal candidate, given his deep understanding of the UK investor landscape and vast experience with AIM. "We believe Bill's expertise will be invaluable to us as we continue the commercialisation of XENOVIEW and look to address the unmet medical needs of patients suffering with chronic respiratory diseases. As a team we look forward to his strategic advice helping us identify and evaluate the various financing options for the Company." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
